JP2024543496A5 - - Google Patents

Info

Publication number
JP2024543496A5
JP2024543496A5 JP2024528580A JP2024528580A JP2024543496A5 JP 2024543496 A5 JP2024543496 A5 JP 2024543496A5 JP 2024528580 A JP2024528580 A JP 2024528580A JP 2024528580 A JP2024528580 A JP 2024528580A JP 2024543496 A5 JP2024543496 A5 JP 2024543496A5
Authority
JP
Japan
Prior art keywords
hypertension
agt
physiological characteristics
condition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024528580A
Other languages
English (en)
Japanese (ja)
Other versions
JP7829035B2 (ja
JP2024543496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/131861 external-priority patent/WO2023088227A1/zh
Publication of JP2024543496A publication Critical patent/JP2024543496A/ja
Publication of JP2024543496A5 publication Critical patent/JP2024543496A5/ja
Priority to JP2026032724A priority Critical patent/JP2026113465A/ja
Application granted granted Critical
Publication of JP7829035B2 publication Critical patent/JP7829035B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024528580A 2021-11-16 2022-11-15 アンギオテンシノゲン(agt)タンパク質の発現を阻害する組成物及び方法 Active JP7829035B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026032724A JP2026113465A (ja) 2021-11-16 2026-03-02 アンギオテンシノゲン(agt)タンパク質の発現を阻害する組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/130832 2021-11-16
CN2021130832 2021-11-16
CN2022081578 2022-03-18
CNPCT/CN2022/081578 2022-03-18
PCT/CN2022/131861 WO2023088227A1 (zh) 2021-11-16 2022-11-15 抑制血管紧张素原(agt)蛋白表达的组合物和方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026032724A Division JP2026113465A (ja) 2021-11-16 2026-03-02 アンギオテンシノゲン(agt)タンパク質の発現を阻害する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2024543496A JP2024543496A (ja) 2024-11-21
JP2024543496A5 true JP2024543496A5 (cg-RX-API-DMAC7.html) 2025-10-21
JP7829035B2 JP7829035B2 (ja) 2026-03-12

Family

ID=86396260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024528580A Active JP7829035B2 (ja) 2021-11-16 2022-11-15 アンギオテンシノゲン(agt)タンパク質の発現を阻害する組成物及び方法
JP2026032724A Pending JP2026113465A (ja) 2021-11-16 2026-03-02 アンギオテンシノゲン(agt)タンパク質の発現を阻害する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026032724A Pending JP2026113465A (ja) 2021-11-16 2026-03-02 アンギオテンシノゲン(agt)タンパク質の発現を阻害する組成物及び方法

Country Status (18)

Country Link
US (3) US20240084304A1 (cg-RX-API-DMAC7.html)
EP (1) EP4435103A4 (cg-RX-API-DMAC7.html)
JP (2) JP7829035B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240103025A9 (cg-RX-API-DMAC7.html)
CN (1) CN116940682A (cg-RX-API-DMAC7.html)
AU (1) AU2022394667A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238865A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001429A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006020A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240196A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000083A (cg-RX-API-DMAC7.html)
EC (1) ECSP24036299A (cg-RX-API-DMAC7.html)
IL (1) IL312811A (cg-RX-API-DMAC7.html)
JO (1) JOP20240109A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005862A (cg-RX-API-DMAC7.html)
PE (1) PE20241933A1 (cg-RX-API-DMAC7.html)
TW (1) TW202334422A (cg-RX-API-DMAC7.html)
WO (1) WO2023088227A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
JP2026520610A (ja) 2023-06-13 2026-06-23 アーナター セラピューティクス インコーポレイテッド アンジオテンシノーゲンのための高度rna標的化技術(arnatar)
WO2025007961A1 (zh) * 2023-07-06 2025-01-09 大睿生物 调控AGT表达的dsRNA分子
TW202509216A (zh) * 2023-07-14 2025-03-01 大陸商北京安龍生物醫藥有限公司 靶向血管收縮素原的寡核苷酸及其用途
WO2024227458A2 (zh) * 2023-08-22 2024-11-07 成都先衍生物技术有限公司 一种靶向AGT基因表达的siRNA及其缀合物和用途
CN118995714B (zh) * 2024-09-26 2025-12-12 杭州天龙药业有限公司 靶向抑制AGT基因表达的siRNA及其在治疗高血压中的应用
WO2025130862A1 (zh) * 2023-12-18 2025-06-26 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120350001A (zh) * 2024-01-22 2025-07-22 尧唐(上海)生物科技有限公司 靶向AGT基因的gRNA及其应用
CN119040330B (zh) * 2024-11-01 2025-03-04 北京悦康科创医药科技股份有限公司 一种调控AGT基因表达的siRNA及其用途
WO2026133251A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use
CN122405619A (zh) * 2025-01-16 2026-07-17 上海民为生物技术有限公司 一种抑制血管紧张素原AGT基因表达的siRNA抑制剂及其应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO1997033623A1 (en) * 1996-03-15 1997-09-18 University Of Florida OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
WO2006081192A2 (en) 2005-01-24 2006-08-03 Alnylam Pharmaceuticals, Inc. Rnai modulation of the nogo-l or nogo-r gene and uses thereof
CN101292034A (zh) 2005-09-15 2008-10-22 桑塔里斯制药公司 抑制apo-b100表达的rna拮抗化合物
CA2622583A1 (en) 2005-09-15 2007-03-22 Henrik Frydenlund Hansen Rna antagonist compounds for the inhibition of apo-b100 expression
US20100137405A1 (en) 2007-05-02 2010-06-03 Merck & Co., Inc RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
US11414664B2 (en) 2008-12-18 2022-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP6010458B2 (ja) 2009-04-03 2016-10-19 ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. 非対称二本鎖rnaによる特異的阻害のための、方法および組成物
US20110196141A1 (en) 2009-09-07 2011-08-11 Council Of Scientific & Industrial Research Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides
WO2011038356A2 (en) 2009-09-25 2011-03-31 Johns Hopkins University Novel liver-targeting agents and their synthesis
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012145582A2 (en) 2011-04-22 2012-10-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibitions of egfr by double-stranded rna
CN102260673A (zh) 2011-07-12 2011-11-30 深圳职业技术学院 靶向人血管紧张素原的rna干扰片段、表达载体与应用
US9796974B2 (en) 2011-11-18 2017-10-24 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
RU2624028C2 (ru) 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
EP3693460A1 (en) * 2012-07-27 2020-08-12 Ionis Pharmaceuticals, Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
TWI553017B (zh) 2012-12-28 2016-10-11 行政院原子能委員會核能研究所 新穎膽道掃描用造影劑及其製造方法
CN103103192A (zh) 2013-01-18 2013-05-15 深圳职业技术学院 靶向血管紧张素原的rna干扰片段、其表达载体、混合克隆细胞株及其应用
EP2958998B1 (en) 2013-02-22 2017-12-27 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2015061536A1 (en) 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
US10010562B2 (en) 2013-11-06 2018-07-03 Merck Sharp & Dohme Corp. Dual molecular delivery of oligonucleotides and peptide containing conjugates
HUE052709T2 (hu) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
SG11201609376SA (en) 2014-05-22 2016-12-29 Alnylam Pharmaceuticals Inc Angiotensinogen (agt) irna compositions and methods of use thereof
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
MX2017011422A (es) 2015-03-17 2017-11-10 Arrowhead Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen del factor xii.
WO2016196111A1 (en) * 2015-06-01 2016-12-08 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting angiotensinogen (agt) and methods of use thereof
JOP20160211B1 (ar) 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
MX392014B (es) * 2015-10-08 2025-03-21 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión de angiotensinógeno.
TWI859114B (zh) 2016-04-11 2024-10-21 加拿大商艾爾布圖斯生技公司 靶向組合物
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
WO2018098328A1 (en) 2016-11-23 2018-05-31 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
US11015198B2 (en) 2017-04-05 2021-05-25 Silence Therapeutics Gmbh Products and compositions
EP3649243A1 (en) 2017-07-07 2020-05-13 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12)
SG11201912178VA (en) 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
CN119120476A (zh) 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
AU2019213004B2 (en) 2018-01-29 2024-03-07 F. Hoffmann-La Roche Ag Process for the preparation of GalNAc oligonucleotide conjugates
WO2019217397A2 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for improving strand biased
TWI851574B (zh) * 2018-05-14 2024-08-11 美商阿尼拉製藥公司 血管收縮素原(AGT)iRNA組成物及其使用方法
AU2019380628B2 (en) 2018-11-13 2024-10-31 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of LPA in a cell
SG11202105900UA (en) 2018-12-10 2021-07-29 Amgen Inc CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
AU2020210900B2 (en) 2019-01-22 2025-04-24 Korro Bio, Inc. RNA-editing oligonucleotides and uses thereof
EP3923989A1 (en) 2019-03-21 2021-12-22 Mitotherapeutix LLC Multivalent ligand clusters for targeted delivery of therapeutic agents
CA3140425A1 (en) 2019-05-23 2020-11-26 Stratos Genomics, Inc. Translocation control elements, reporter codes, and further means for translocation control for use in nanopore sequencing
IL291251B2 (en) 2019-09-10 2026-06-01 Daiichi Sankyo Co Limited CONJUGATE OF GalNAC-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
IL292865A (en) 2019-11-13 2022-07-01 Alnylam Pharmaceuticals Inc Methods and preparations for the treatment of angiotensinogen-related disorder - (agt)
JP7827623B2 (ja) 2019-12-09 2026-03-10 アムジエン・インコーポレーテツド LPA発現を阻害するためのRNAiコンストラクト及び方法
JP2023515664A (ja) 2020-03-06 2023-04-13 アリゴス セラピューティクス,インコーポレーテッド 修飾された短い干渉核酸(siNA)分子およびそれらの使用
US11649458B2 (en) * 2020-05-05 2023-05-16 University Of Kentucky Research Foundation Inhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome
MX2022014606A (es) 2020-05-22 2023-03-08 Wave Life Sciences Ltd Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
WO2022028457A1 (zh) 2020-08-04 2022-02-10 上海拓界生物医药科技有限公司 抑制凝血因子XI表达的siRNA、组合物及其医药用途
KR20250077604A (ko) 2020-08-05 2025-05-30 다이서나 파마수이티컬, 인크. Lpa 발현을 저해하기 위한 조성물 및 방법
EP4229201A1 (en) 2020-10-16 2023-08-23 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
CN114763547A (zh) 2021-01-14 2022-07-19 施能康生物科技有限公司 靶向血管紧张素原的核酸及其用途
CN116761616A (zh) * 2021-01-22 2023-09-15 阿耐拉姆制药公司 经修饰的双链寡核苷酸
EP4176061A1 (en) 2021-01-30 2023-05-10 E-Therapeutics plc Nucleic acids containing abasic nucleotides
WO2022232650A1 (en) 2021-04-30 2022-11-03 Ionis Pharmaceuticals, Inc. Methods for reducing agt expression
IL309296A (en) 2021-06-30 2024-02-01 Alnylam Pharmaceuticals Inc Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
CA3228255A1 (en) * 2021-08-04 2023-02-09 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing angiotensinogen (agt)
US20250283076A1 (en) 2021-09-14 2025-09-11 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041079A1 (zh) 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途
US20240401045A1 (en) 2021-10-01 2024-12-05 Adarx Pharmaceuticals, Inc. Angiotensinogen-modulating compositions and methods of use thereof
CN113862268B (zh) * 2021-10-20 2025-05-13 厦门甘宝利生物医药有限公司 Agt抑制剂及其用途
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
IL315862A (en) * 2022-04-01 2024-11-01 Adarx Pharmaceuticals Inc Angiotensinogen modulators and methods of using them
WO2024013334A1 (en) * 2022-07-15 2024-01-18 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of agt in a cell
WO2024031101A1 (en) * 2022-08-05 2024-02-08 Sanegene Bio Usa Inc. Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
TW202430193A (zh) 2022-12-20 2024-08-01 美商靖因藥業(上海)有限公司 靶向agt之聚核酸分子及其用途
WO2024187193A2 (en) 2023-03-09 2024-09-12 Basecure Therapeutics Llc Compositions and methods for inhibition of expression of angiotensinogen (agt) genes

Similar Documents

Publication Publication Date Title
JP2025504863A5 (cg-RX-API-DMAC7.html)
JP7829035B2 (ja) アンギオテンシノゲン(agt)タンパク質の発現を阻害する組成物及び方法
JP2023502038A5 (cg-RX-API-DMAC7.html)
JP7833044B2 (ja) タンパク質LPA(Apo(a))の発現を阻害するための組成物及び方法
JP2024531914A5 (cg-RX-API-DMAC7.html)
IL292865A (en) Methods and preparations for the treatment of angiotensinogen-related disorder - (agt)
US8637482B2 (en) Methods for treating chronic kidney disease
JP2020503070A (ja) α−1アンチトリプシン(AAT)RNAi剤、AAT RNAi剤を含む組成物、及び使用方法。
CN116456990A (zh) 用靶向LPA的RNAi构建体治疗动脉粥样硬化性心血管疾病的方法
KR20240053627A (ko) 안지오포이에틴-유사 3(angptl3) 단백질의 발현을 억제하기 위한 조성물 및 방법
JP2024527304A (ja) アンジオテンシノーゲン(agt)関連障害を治療するための方法および組成物
JP2024527304A5 (cg-RX-API-DMAC7.html)
JP2022535127A (ja) アルファ-1アンチトリプシン欠乏症(aatd)の治療法
CA2860676A1 (en) Organic compositions to treat beta-catenin-related diseases
US20190071670A1 (en) Methods Of Treatment For Alpha-1 Antitrypsin Deficiency
CN119137272A (zh) 血管紧张素原调节组合物和其使用方法
CN114555188A (zh) 治疗apoc3相关疾病和病症的方法
JP2023541170A (ja) Z-aatタンパク質のレベルを低下させる方法
WO2023143483A1 (en) Compositions and methods for inhibiting expression of prekallikrein (pkk) protein
JP2025508324A5 (cg-RX-API-DMAC7.html)
JP2022546570A5 (cg-RX-API-DMAC7.html)
RU2024116174A (ru) Композиции и способы для подавления экспрессии белка ангиотензиногена (agt)
EP4269586A1 (en) Targeting micro rna for treatment of heart failure with preserved ejection fraction (hfpef)
HK40115058A (en) Composition and method for inhibiting angiotensinogen (agt) protein expression
HK40115145A (en) Angiotensinogen-modulating compositions and methods of use thereof